Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Application of lung volume reduction surgery for a child with filamin A (FLNA) mutations.  Pediatric Pulmonology.  57:224-230. 2022
2021 Noninvasive oscillometry to measure pulmonary mechanics in preterm infants.  American Journal of Respiratory and Critical Care Medicine.  204:485-488. 2021
2020 Dupilumab for chronic eosinophilic pneumonia.  Pediatric Pulmonology.  55:3229-3230. 2020
2019 Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study.  The Lancet Respiratory Medicine.  7:1027-1038. 2019
2019 Area deprivation as a risk factor for methicillin-resistant Staphylococcus aureus infection in pediatric cystic fibrosis.  The Pediatric Infectious Disease Journal.  38:E285-E289. 2019
2019 Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.  The Lancet Respiratory Medicine.  7:802-809. 2019
2017 Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life.  JAMA Pediatrics.  171:546-554. 2017
2017 Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.  Thorax.  72:318-326. 2017
2016 Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.  Pediatric Pulmonology.  51:1168-1176. 2016
2015 Thymic hyperplasia and chylothorax.  Pediatric Pulmonology.  50:E37-E39. 2015
2015 Outcomes and treatment of chronic methicillin-resistant Staphylococcus aureus differs by staphylococcal cassette chromosome mec (SCCmec) type in children with cystic fibrosis.  Journal of the Pediatric Infectious Diseases Society.  4:225-231. 2015
2015 Multicenter observational study on factors and outcomes associated with various methicillin-resistant Staphylococcus aureus types in children with cystic fibrosis.  Annals of the American Thoracic Society.  12:864-871. 2015
2012 Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.  Pediatric Pulmonology.  47:1113-1122. 2012
2012 Inhibition of p21 activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways.  PLoS One.  7. 2012
2011 Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3a4 inhibitor.  Annals of Pharmacotherapy.  45. 2011
2011 Targeting early events in cystic fibrosis disease pathogenesis.  Drugs of the Future.  36:133-140. 2011
2010 Cystic fibrosis pulmonary guidelines: Pulmonary complications: Hemoptysis and pneumothorax.  American Journal of Respiratory and Critical Care Medicine.  182:298-306. 2010
2008 The congenital porto-caval fistula: A unique presentation and novel intervention.  Pediatric Pulmonology.  43:196-199. 2008
2007 Development of pulmonary hypertension in an infant treated with diazoxide.  Journal of Pediatric Endocrinology and Metabolism.  20:939-944. 2007

Chapter

Year Title Altmetric
2016 Restoration of CFTR function with small-molecule modulators.  406-423. 2016

Principal Investigator On

Investigator On

  • A Multi-Center Study of a New Method of Sweat Testing: The CF Quantum Sweat Test  awarded by University of Wisconsin-Madison
  • First/Second Year Clinical Fellowship  awarded by Cystic Fibrosis Foundation ^
  • Functional Anatomic Imaging of CF Patients with Early Lung Disease Using microOCT  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PROQR THERAPEUTICS
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by CELTAXSYS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by PARION SCIENCES, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL
  • The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF  awarded by CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation ^
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research  awarded by Cystic Fibrosis Foundation ^
  • UAB Pediatric Pulmonary Center  awarded by Health Resources and Services Administration/DHHS
  • UAB Pediatric Pulmonary Center  awarded by Health Resources and Services Administration/DHHS
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^

    • Education And Training

  • Sacred Heart Hospital, Internship
  • Sacred Heart Hospital, Residency
  • Indiana University Medical Center, Postdoctoral Fellowship
  • Doctor of Medicine in Pediatrics Residency Program, Louisiana State University System : University of New Orleans 2000

    • Full Name

  • Wynton Hoover